Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation

被引:94
|
作者
Yoshida, Tatsuya [1 ,2 ,3 ]
Ishii, Genichiro [1 ]
Goto, Koichi [2 ]
Neri, Shinya [1 ]
Hashimoto, Hiroko [1 ]
Yoh, Kiyotaka [2 ]
Niho, Seiji [2 ]
Umemura, Shigeki [2 ]
Matsumoto, Shingo [2 ]
Ohmatsu, Hironobu [2 ]
Iida, Shinsuke [3 ]
Niimi, Akio [3 ]
Nagai, Kanji [2 ]
Ohe, Yuichiro [2 ]
Ochiai, Atsushi [1 ]
机构
[1] Natl Canc Ctr Hosp East, Div Pathol, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba 2778577, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Nagoya, Aichi, Japan
关键词
TYROSINE KINASE INHIBITORS; PREDICTS POOR-PROGNOSIS; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; OPEN-LABEL; GEFITINIB; GROWTH; CHEMOTHERAPY; STROMA; POLYMORPHISM;
D O I
10.1158/1078-0432.CCR-14-0846
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The biologic characteristics of microenvironmental constituents, especially cancer-associated fibroblasts (CAF), can be key regulators of the cellular sensitivity to molecular-targeted therapy. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have marked therapeutic effects against non-small cell lung cancer (NSCLC) with EGFR mutations, but some patients have exhibited primary resistance to EGFR-TKIs. We recently reported that podoplanin-positive fibroblasts are associated with a tumor-promoting phenotype of CAFs in lung adenocarcinoma. The aim of this study was to evaluate whether the susceptibility of NSCLC to EGFR-TKIs could be affected by podoplanin-expressing CAFs. Experimental Design: We evaluated the EGFR-TKI sensitivity of EGFR-mutant lung adenocarcinoma cell lines cocultured with podoplanin-expressing CAFs. We also examined the association between the expression of podoplanin in CAFs in surgical specimens and EGFR-TKI response of postoperative recurrent patients with EGFR mutations (N = 106). Results: Lung adenocarcinoma cell lines became more resistant to EGFR-TKI when cocultured with podoplanin-expressing CAFs, compared with control CAFs in vitro. The knockdown of podoplanin expression on CAFs cancelled the resistance to EGFR-TKIs in cancer cells. Compared with control CAFs, the cancer cells that were cocultured with podoplanin-positive CAFs continued to exhibit significantly higher p-ERK levels after treatment with gefitinib. Furthermore, postoperative recurrent patients with podoplanin-positive CAFs had a significantly lower overall response rate to EGFR-TKIs compared with those with podoplanin-negative CAFs (53% vs. 83%; P < 0.01). Conclusions: Podoplanin-positive CAFs play an important role in primary resistance to EGFR-TKIs and may be an ideal therapeutic target for use in combination therapy with EGFR-TKIs. (C) 2014 AACR.
引用
收藏
页码:642 / 651
页数:10
相关论文
共 50 条
  • [1] THE RESISTANCE TO EGFR-TKIS IN LUNG CANCER
    Yamada, T.
    Yano, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 77 - 77
  • [2] EGFR-TKIs compared with radiotherapy for patients of stage IV lung adenocarcinoma with EGFR mutation
    Wang, Y.
    Yu, W.
    Shi, J.
    Qiu, M.
    Jiang, N.
    Wang, Z.
    Yang, J.
    Song, M.
    Jia, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S976 - S976
  • [3] Podoplanin-positive cancer-associated fibroblasts predict poor prognosis in lung cancer patients
    Hu, Guoming
    Zhong, Kefang
    Chen, Wei
    Wang, Shimin
    Huang, Liming
    ONCOTARGETS AND THERAPY, 2018, 11 : 5607 - 5619
  • [4] Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
    Zhou, Jia-Ying
    Liu, Si-Yang
    Wu, Yi-Long
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 589 - 599
  • [5] Cancer-Associated Fibroblasts Derived from EGFR-TKI-Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs
    Mink, Sheldon R.
    Vashistha, Surabhi
    Zhang, Wenxuan
    Hodge, Amanda
    Agus, David B.
    Jain, Anjali
    MOLECULAR CANCER RESEARCH, 2010, 8 (06) : 809 - 820
  • [6] Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma harboring EGFR-RAD51 Fusion: A Brief Report
    Wang, H.
    Peng, K.
    Li, A.
    Wang, Z.
    Xie, Z.
    Chen, H.
    Wu, Y.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S624 - S624
  • [7] Podoplanin-Positive Fibroblasts Enhance Lung Adenocarcinoma Tumor Formation: Podoplanin in Fibroblast Functions for Tumor Progression
    Hoshino, Ayuko
    Ishii, Genichiro
    Ito, Takashi
    Aoyagi, Kazuhiko
    Ohtaki, Yoichi
    Nagai, Kanji
    Sasaki, Hiroki
    Ochiai, Atsushi
    CANCER RESEARCH, 2011, 71 (14) : 4769 - 4779
  • [8] The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
    Sun, Li
    Li, Yao-Yong
    Ma, Jie-Tao
    Zhang, Shu-Ling
    Huang, Le-Tian
    Han, Cheng-Bo
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 1834 - 1844
  • [9] Transitional CXCL14+ cancer-associated fibroblasts enhance tumour metastasis and confer resistance to EGFR-TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma
    Xu, Weijiao
    Yang, Haitang
    Xu, Ke
    Zhu, Anshun
    Hall, Sean R. R.
    Jia, Yunxuan
    Zhao, Baicheng
    Zhang, Enshuo
    Liu, Gang
    Xu, Jianlin
    Marti, Thomas M.
    Peng, Ren-Wang
    Dorn, Patrick
    Niu, Yongliang
    Pan, Xufeng
    Zhang, Yajuan
    Yao, Feng
    CLINICAL AND TRANSLATIONAL MEDICINE, 2025, 15 (04):
  • [10] Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
    Ngamchokwathana, C.
    Santisukwongchote, S.
    Zungsontiporn, N.
    Sitthideatphaiboon, P.
    Chantranuwat, P.
    Vinayanuwattikun, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S204 - S204